XNAS 05 Sep, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 29 Aug 2025 | 8,836 | 38,532 | - | 25.1 | 221,607 | Common Stock |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.18 per share. | 29 Aug 2025 | 748 | 47,368 | - | 25.2 | 18,835 | Common Stock |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.97 per share. | 26 Aug 2025 | 16,098 | 48,116 | - | 26.0 | 418,065 | Common Stock |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 26 Aug 2025 | 3,700 | 67,832 | - | 25.1 | 92,981 | Common Stock |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 26 Aug 2025 | 3,618 | 64,214 | - | 25.1 | 90,812 | Common Stock |
| Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 26 Aug 2025 | 7,426 | 547,343 | - | 25.0 | 185,714 | Common Stock |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Aug 2025 | 7,426 | 554,769 | - | 6.1 | 45,373 | Common Stock |
| Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 24.96 per share. | 26 Aug 2025 | 17,574 | 547,343 | - | 25.0 | 438,647 | Common Stock |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 26 Aug 2025 | 17,574 | 564,917 | - | 6.1 | 107,377 | Common Stock |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 17,574 | 210,568 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2025 | 7,426 | 203,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael Cloonan | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 20 Aug 2025 | 25,000 | 547,343 | - | 22.8 | 568,750 | Common Stock |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.11 per share. | 20 Aug 2025 | 25,000 | 572,343 | - | 6.1 | 152,750 | Common Stock |
| Michael Cloonan | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2025 | 25,000 | 228,142 | - | - | Non-Qualified Stock Option (right to buy) | |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 21.08 per share. | 19 Aug 2025 | 34,500 | 89,032 | - | 21.1 | 727,260 | Common Stock |
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 19 Aug 2025 | 17,500 | 71,532 | - | 22.7 | 397,075 | Common Stock |
| Laurie D. Stelzer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Marcella Kuhlman Ruddy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| H. Edward Fleming | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Joanne Louise Viney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Joshua Resnick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Bruce Booth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Peter A. Thompson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Paul J. Clancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 19,959 | 19,959 | - | - | Non-Qualified Stock Option (right to buy) | |
| Peter A. Thompson | Director | 10 Feb 2025 | 3,154,959 | 3,154,959 | - | - | Common Stock | ||
| Peter A. Thompson | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 10 Feb 2025 | 550,000 | 3,704,959 | - | 18 | 9,900,000 | Common Stock |
| Peter A. Thompson | Director | 10 Feb 2025 | 2,048,760 | 0 | - | - | Series C convertible preferred stock | ||
| Peter A. Thompson | Director | 10 Feb 2025 | 2,560,951 | 0 | - | - | Series B convertible preferred stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 61,463 | 0 | - | - | Series C convertible preferred stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 1,092,504 | 0 | - | - | Series C convertible preferred stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 2,886,293 | 2,886,293 | - | - | Common Stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 747,727 | 747,727 | - | - | Common Stock | ||
| Bruce Booth | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 10 Feb 2025 | 60,000 | 807,727 | - | 18 | 1,080,000 | Common Stock |
| Bruce Booth | Director | 10 Feb 2025 | 1,051,051 | 0 | - | - | Series Seed convertible preferred stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 1,806,317 | 0 | - | - | Series A convertible preferred stock | ||
| Bruce Booth | Director | 10 Feb 2025 | 1,298,332 | 0 | - | - | Series B convertible preferred stock | ||
| Elena H. Ridloff | CFO & Head of Corp. Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 157,820 | 157,820 | - | - | Stock Option (Right to Buy) | |
| Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 450,252 | 450,252 | - | - | Stock Option (Right to Buy) | |
| Joanne Louise Viney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 39,919 | 39,919 | - | - | Stock Option (Right to Buy) | |
| Marcella Kuhlman Ruddy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 39,919 | 39,919 | - | - | Stock Option (Right to Buy) | |
| Charlotte McKee | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 148,536 | 148,536 | - | - | Stock Option (Right to Buy) |